top of page

The Platform: Dendritic cell-targeted immunotherapy​

thech.png

TNM FOR SOLID TUMORS:​

1. Overcomes T-cell exhaustion by combining the delivery of short (MHC class I) and long (MHC class II) peptide sequences with regulators of immune suppressors (e.g., siRNA targeting immune checkpoints and TLR9 ligand to DC):​​

2. Activates and matures DC while trafficking to lymph nodes and interacting with T and
    cells:​

  • Activation of IFN- producing CD4+ T helper cells​

  • Reduction or non-activation of Treg cells​

  • Effector Cytotoxic T Lymphocytes (CTL)​

  • Induction of Germinal center B cell responses

3. Regulates tumor-infiltrating immune cell profiling:​

  • Extensive amounts of CTL​

  • High levels of cytotoxic DC (CD8+ DC)​

  • High levels of IFN-, TNF-, IL-2 

4. Triggers strong humoral immunity based on high-affinity antibodies and memory B cells.​

bottom of page